1
|
Sheridan C, O'Connor MC, Sitton B, Bass J, Shahwan KT, Carr DR. Nevus Spilus With Dermatoheliosis: A Histologic Mimicker of Melanoma in Situ at Melanoma Excision Margins. Am J Dermatopathol 2023; 45:e83-e85. [PMID: 37462160 DOI: 10.1097/dad.0000000000002493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/27/2023]
Abstract
ABSTRACT Nevus spilus, or speckled lentiginous nevus, is a relatively common lesion that presents at birth or in early childhood. It consists of a background tan patch, which appears similar to a café au lait macule or lentigo simplex on histology, studded with various types of nevi. Rarely, these nevi can undergo malignant transformation to melanoma. When melanoma develops within a heavily photodamaged nevus spilus, evaluating excision margins may be challenging because the combined histologic features of nevus spilus and severe dermatoheliosis can mimic melanoma in situ. We report a case of an elderly man with extensive sun damage who developed malignant melanoma within an occult nevus spilus, resulting in multiple excisions with false-positive margins.
Collapse
Affiliation(s)
- Connor Sheridan
- University of North Dakota School of Medicine, Grand Forks, ND
| | - Megan C O'Connor
- Department of Dermatology, Health Partners Institute, St. Louis Park, MN
| | - Beau Sitton
- The Ohio State University College of Medicine, Columbus, OH
| | - Jonathan Bass
- Departments of Dermatology and Pathology, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
| | - Kathryn T Shahwan
- University of North Dakota School of Medicine, Grand Forks, ND
- Department of Dermatology, Altru Health System, Grand Forks, ND; and
- Department of Dermatology, The Ohio State University Medical Center, Columbus, OH
| | - David R Carr
- Department of Dermatology, The Ohio State University Medical Center, Columbus, OH
| |
Collapse
|
2
|
Martins da Silva V, Martinez-Barrios E, Tell-Martí G, Dabad M, Carrera C, Aguilera P, Brualla D, Esteve-Codina A, Vicente A, Puig S, Puig-Butillé JA, Malvehy J. Genetic Abnormalities in Large to Giant Congenital Nevi: Beyond NRAS Mutations. J Invest Dermatol 2018; 139:900-908. [PMID: 30359577 DOI: 10.1016/j.jid.2018.07.045] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Revised: 07/24/2018] [Accepted: 07/26/2018] [Indexed: 02/03/2023]
Abstract
Large and giant congenital melanocytic nevi (CMN) are rare melanocytic lesions mostly caused by postzygotic NRAS alteration. Molecular characterization is usually focused on NRAS and BRAF genes in a unique biopsy sample of the CMN. However, large/giant CMN may exhibit phenotypic differences among distinct areas, and patients differ in features such as presence of multiple CMN or spilus-like lesions. Herein, we have characterized a series of 21 large/giant CMN including patients with spilus-type nevi (9/21 patients, 42.8%). Overall, 53 fresh frozen biopsy samples corresponding to 40 phenotypically characterized areas of large/giant CMNs and 13 satellite lesions were analyzed with a multigene panel and RNA sequencing. Mutational screening showed mutations in 76.2% (16/21) of large/giant CMNs. A NRAS mutation was found in 57.1% (12/21) of patients, and mutations in other genes such as BRAF, KRAS, APC, and MET were detected in 14.3% (3/21) of patients. RNA sequencing showed the fusion transcript ZEB2-ALK and SOX5-RAF1 in large/giant CMN from two patients without missense mutations. Both alterations were not detected in unaffected skin and were detected in different areas of affected skin. These findings suggest that large/giant CMN may result from distinct molecular events in addition to NRAS mutations, including point mutations and fusion transcripts.
Collapse
Affiliation(s)
- Vanessa Martins da Silva
- Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain
| | - Estefania Martinez-Barrios
- Department of Biochemical and Molecular Genetics, Hospital Clínic, IDIBAPS, University of Barcelona, Catalonia, Spain
| | - Gemma Tell-Martí
- Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Catalonia, Spain
| | - Marc Dabad
- CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain; Universitat Pompeu Fabra, Barcelona, Catalonia, Spain
| | - Cristina Carrera
- Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Catalonia, Spain
| | - Paula Aguilera
- Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Catalonia, Spain
| | - Daniel Brualla
- Department of Pediatric Dermatology, Hospital San Joan de Déu, Barcelona, Spain
| | - Anna Esteve-Codina
- CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain; Universitat Pompeu Fabra, Barcelona, Catalonia, Spain
| | - Asunción Vicente
- Department of Pediatric Dermatology, Hospital San Joan de Déu, Barcelona, Spain
| | - Susana Puig
- Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Catalonia, Spain
| | - Joan Anton Puig-Butillé
- Department of Biochemical and Molecular Genetics, Hospital Clínic, IDIBAPS, University of Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Catalonia, Spain; Molecular Biology CORE, Hospital Clínic, IDIBAPS, University of Barcelona, Catalonia, Spain.
| | - Josep Malvehy
- Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain; Department of Biochemical and Molecular Genetics, Hospital Clínic, IDIBAPS, University of Barcelona, Catalonia, Spain
| |
Collapse
|